CBUS vs OFIX vs NVCR vs PGEN vs FATE

For growth investors, NovoCure Limited (NVCR) is the stronger pick with 8.

3% revenue growth year-over-year, versus -51. 2% for Fate Therapeutics, Inc. (FATE). Analysts rate Cibus, Inc. (CBUS) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Precigen, Inc.

(PGEN) delivered a total return of -36. 5%, compared to -99. 3% for Cibus, Inc. (CBUS). Over 10 years, the gap is even starker: FATE returned +40. 5% versus CBUS's -99. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Orthofix Medical Inc.

(OFIX) is the lower-risk stock at 1. 21β versus Cibus, Inc. 's 3. 12β — meaning CBUS is approximately 157% more volatile than OFIX relative to the S&P 500. On balance sheet safety, Precigen, Inc. (PGEN) carries a lower debt/equity ratio of 14% versus 151% for Cibus, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), NovoCure Limited (NVCR) is pulling ahead at 8.

3% versus -51. 2% for Fate Therapeutics, Inc. (FATE). On earnings-per-share growth, the picture is similar: Cibus, Inc. grew EPS 74. 3% year-over-year, compared to -20. 5% for Precigen, Inc.. Over a 3-year CAGR, CBUS leads at 185. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Orthofix Medical Inc.

(OFIX) is the more profitable company, earning -11. 2% net margin versus -34. 9% for Cibus, Inc. — meaning it keeps -11. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: OFIX leads at -8. 3% versus -34. 4% for PGEN. At the gross margin level — before operating expenses — NVCR leads at 74. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Orthofix Medical Inc.

(OFIX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 21)). Cibus, Inc. (CBUS) carries a higher beta of 3. 12 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (OFIX: -72. 0%, CBUS: -99. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.